Primary ciliary dyskinesia: First health-related quality-of-life measures for pediatric patients

Annals of the American Thoracic Society

Volumn 13, Issue 10, 2016, Pages 1726-1735

  Dell, Sharon D ^a,b   Leigh, Margaret W ^c   Lucas, Jane S ^d,e   Ferkol, Thomas W ^f   Knowles, Michael R ^c   Alpern, Adrianne ^g   Behan, Laura ^c,d,h   Morris, Anjana M ^g   Hogg, Claire ⁱ   Galvin, Audrey Dunn ^h   Quittner, Alexandra L ^g  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f WASHINGTON UNIVERSITY   (United States)

^g University of Miami   (United States)

^h UNIVERSITY COLLEGE CORK   (Ireland)

ⁱ ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Health related quality of life; Parent proxy; Patient reported outcomes; Pediatric; Primary ciliary dyskinesia

Indexed keywords

ADOLESCENT; ARTICLE; BODY IMAGE; BODY WEIGHT; CHILD; CILIARY DYSKINESIA; CONCEPTUAL FRAMEWORK; DELPHI STUDY; DISEASE SEVERITY; ETHNICITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICAN; OPEN ENDED QUESTIONNAIRE; PATIENT-REPORTED OUTCOME; PSYCHOLOGIST; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; SOCIAL INTERACTION; SOCIAL STATUS; CHILD PARENT RELATION; CULTURAL COMPETENCE; INFORMATION PROCESSING; INTERNATIONAL COOPERATION; INTERVIEW; KARTAGENER SYNDROME; PSYCHOLOGY; VALIDATION STUDY;

ADOLESCENT; CHILD; CULTURAL COMPETENCY; FEMALE; FOCUS GROUPS; HUMANS; INTERNATIONAL COOPERATION; INTERVIEWS AS TOPIC; KARTAGENER SYNDROME; MALE; PARENTING; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84992623614     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201603-198OC     Document Type: Article

References (26)

1. Knowles MR, Daniels LA, Davis SD, Zariwala MA, Leigh MW. Primary ciliary dyskinesia: recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med 2013; 188:913-922.
2. Shapiro AJ, Zariwala MA, Ferkol T, Davis SD, Sagel SD, Dell SD, Rosenfeld M, Olivier KN, Milla C, Daniel SJ, et al.; Genetic Disorders of Mucociliary Clearance Consortium. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr Pulmonol 2016;51:115-132.
3. Quittner AL, Modi A, Cruz I. Systematic review of health-related quality of life measures for children with respiratory conditions. Paediatr Respir Rev 2008;9:220-232.
4. Maglione M, Bush A, Montella S, Mollica C, Manna A, Esposito A, Santamaria F. Progression of lung disease in primary ciliary dyskinesia: is spirometry less accurate than CT? Pediatr Pulmonol 2012;47:498-504.
5. Green K, Buchvald FF, Marthin JK, Hanel B, Gustafsson PM, Nielsen KG. Ventilation inhomogeneity in children with primary ciliary dyskinesia. Thorax 2012;67:49-53.
6. Irving SJ, Ives A, Davies G, Donovan J, Edey AJ, Gill SS, Nair A, Saunders C, Wijesekera NT, Alton EW, et al. Lung clearance index and high-resolution computed tomography scores in primary ciliary dyskinesia. Am J Respir Crit Care Med 2013;188:545-549.
7. Boon M, Vermeulen FL, Gysemans W, Proesmans M, Jorissen M, De Boeck K. Lung structure-function correlation in patients with primary ciliary dyskinesia. Thorax 2015;70:339-345.
8. U.S. Department of Health and Human Services; Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009 Dec [updated 2009 Dec; accessed 2015 September 24]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf
9. Apolone G, De Carli G, Brunetti M, Garattini S. Health-related quality of life (HR-QOL) and regulatory issues: an assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmacoeconomics 2001;19:187-195.
10. European Medicines Agency; Committee for Medicinal Products for Human Use (CMHP). Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. 2005 [accessed 2015 August 4]. Available from: http://www.ema.europa.eu/ema/index.jsp? curl=pages/regulation/general/general-content-001238. jsp&mid=WC0b01ac0580032ec4
11. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: A review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004;25:535-552.
12. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of the Cystic Fibrosis Questionnaire in the United States: A health-related quality-of-life measure for cystic fibrosis. Chest 2005;128:2347-2354.
13. Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc 2007;4:378-386.
14. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-928.
15. Landgraff J, Abetz L. Measuring health outcomes in pediatric populations: issues in psychometrics and application. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven; 1996. pp. 793-802.
16. Dell S, Leigh M, Ferkol T, Knowles M, Alpern A, Behan L, Hogg C, DunnGalvin A, Lucas JS, Quittner AL. Development of pediatric cross-cultural patient-reported outcome measures: QOL-PCD [abstract]. Presented at the European Respiratory Society Annual Congress, September 2014, 44.
17. Davis SD, Ferkol TW, Rosenfeld M, Lee HS, Dell SD, Sagel SD, Milla C, Zariwala MA, Pittman JE, Shapiro AJ, et al. Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. Am J Respir Crit Care Med 2015;191:316-324.
18. Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Baktai G, Bartoloni L, Eber E, Escribano A, Haarman E, et al. Primary ciliary dyskinesia: A consensus statement on diagnostic and treatment approaches in children. Eur Respir J 2009;34:1264-1276.
19. O'Reilly M, Parker N. "Unsatisfactory saturation": A critical exploration of the notion of saturated sample sizes in qualitative research. Qual Res 2013;13:190-197.
20. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376-380.
21. Beatty PC, Willis GB. Research synthesis: The practice of cognitive interviewing. Public Opin Q 2007;71:287-311.
22. Lucas JS, Behan L, Dunn Galvin A, Alpern A, Morris AM, Carroll MP, Knowles MR, Leigh MW, Quittner AL. A quality-of-life measure for adults with primary ciliary dyskinesia: QOL-PCD. Eur Respir J 2015; 46:375-383.
23. Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, Konstan MW. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res 2012;21: 1267-1278.
24. Quittner AL, O'Donnell AE, Salathe MA, Lewis SA, Li X, Montgomery AB, O'Riordan TG, Barker AF. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax 2015;70:12-20.
25. Quittner AL, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS, Metersky ML, Flume PA, Lewis SA, McKevitt M, et al. A preliminary Quality of Life Questionnaire-Bronchiectasis: A patientreported outcome measure for bronchiectasis. Chest 2014;146: 437-448.
26. Alpern AN, Brumback LC, Ratjen F, Rosenfeld M, Davis SD, Quittner AL. Initial evaluation of the Parent Cystic Fibrosis Questionnaire- Revised (CFQ-R) in infants and young children. J Cyst Fibros 2015; 14:403-411.